Antibiotics Market Report by Action Mechanism (Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, Mycolic Acid Inhibitors, and Others), Drug Class (Cephalosporin, Penicillin, Fluoroquinolone, Macrolide, Carbapenem, Aminoglycoside, and Others), Spectrum of Activity (Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics), Route of Administration (Oral, Parenteral, Topical, and Others), End User (Hospitals, Specialty Clinics, and Others), and Region 2024-2032

Antibiotics Market Report by Action Mechanism (Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, Mycolic Acid Inhibitors, and Others), Drug Class (Cephalosporin, Penicillin, Fluoroquinolone, Macrolide, Carbapenem, Aminoglycoside, and Others), Spectrum of Activity (Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics), Route of Administration (Oral, Parenteral, Topical, and Others), End User (Hospitals, Specialty Clinics, and Others), and Region 2024-2032

Report Format: PDF+Excel | Report ID: SR112024A3569
Buy Now

Market Overview:

The global antibiotics market size reached US$ 51.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 70.7 Billion by 2032, exhibiting a growth rate (CAGR) of 3.5% during 2024-2032. The growing prevalence of pneumonia, tuberculosis, and other infectious diseases among individuals, rising occurrence of antimicrobial resistance (AMR), and technological advancements in biotechnology and drug discovery techniques are some of the major factors propelling the market.

Report Attribute
Key Statistics
Base Year
2023
Forecast Years
2024-2032
Historical Years
2018-2023
Market Size in 2023 US$ 51.4 Billion
Market Forecast in 2032 US$ 70.7 Billion
Market Growth Rate 2024-2032 3.5%


Antibiotics are a class of medications that are used to treat bacterial infections. They are widely available in various forms, such as pills, capsules, injections, creams, and ointments. They either kill bacteria or inhibit their growth to effectively eliminate infections. They target specific mechanisms or structures within bacterial cells and interfering with their vital functions and preventing their reproduction. Besides this, they assist in enhancing the immune system of individuals. As a result, antibiotics are utilized to treat various diseases, such as urinary tract infections (UTI), respiratory tract infections, skin infections, and certain sexually transmitted diseases among individuals.

Global Antibiotics Market

At present, the increasing prevalence of numerous chronic diseases among the masses around the world is contributing to the growth of the market. Additionally, the wide availability of antibiotics through online and offline stores across the globe is strengthening the growth of the market. Apart from this, the growing demand for topical antibiotics, as they minimize the risk of surgical site infections among individuals, is positively influencing the market. Moreover, the increasing employment of antibiotics in livestock farming to safeguard animal health and welfare and support food safety is bolstering the growth of the market. In line with this, the rising demand for antibiotics among the geriatric population is supporting the growth of the market. Furthermore, the increasing consumer awareness about preventive healthcare measures is impelling the growth of the market.

Antibiotics Market Trends/Drivers:

Rising prevalence of infectious diseases

There is a rise in the prevalence of infectious diseases, such as pneumonia, tuberculosis, urinary tract infections (UTI), gastrointestinal infections, and sepsis, among the masses across the globe. People are increasingly suffering from these diseases due to inadequate sanitation, which contributes to the spread of bacterial infections. In addition, the emergence of drug-resistant bacteria is increasing the demand for antibiotics. There is a rise in the demand for effective antibiotics that assist in treating these infections. Antibiotics are specifically designed to target and eliminate bacterial infections. They effectively kill bacteria in the body and promote healing among individuals. Furthermore, antibiotics are used under the guidance of healthcare professionals to optimize patient outcomes.

Increasing occurrence of antimicrobial resistance (AMR)

There is a rise in the occurrence of antimicrobial resistance (AMR) across the globe, which is driving the antibiotics market. AMR occurs when bacteria, viruses, parasites, or fungi evolve and become resistant to the drugs used to treat them. It reduces the effectiveness of antibiotics and causes longer and more severe infections, increased healthcare costs, and high mortality rates among individuals. Overuse and misuse of antibiotics are contributing to the development of drug-resistant bacteria, which makes traditional antibiotics less effective. In addition, multidrug-resistant strains, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Carbapenem-resistant Enterobacteriaceae (CRE), are more prevalent. This necessitates the development of new antibiotics or alternative treatments to combat these resistant strains.

Technological advancements in antibiotics

Innovations in biotechnology, molecular biology, and drug discovery techniques assist in improving the efficiency and effectiveness of antibiotic development. Genomics and high-throughput screening allow the identification of potential drug targets and the screening of large compound libraries. Moreover, computer-aided drug design enables the prediction of drug efficacy and optimizes antibiotic candidates. These technological advancements streamline the antibiotic discovery process and reduce the time and costs associated with traditional methods. Additionally, advancements in diagnostic techniques, such as rapid pathogen identification and susceptibility testing, assist in appropriate antibiotic selection and prescribing that provides enhanced patient outcomes. Furthermore, technological advancements aid in the development of new and more potent antibiotics to address infectious diseases and antimicrobial resistance.

Antibiotics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global antibiotics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on action mechanism, drug class, spectrum of activity, route of administration and end user.

Breakup by Action Mechanism:

Antibiotics Market

  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • Mycolic Acid Inhibitors
  • Others


Cell wall synthesis inhibitors represent the largest market segment

The report has provided a detailed breakup and analysis of the market based on the action mechanism. This includes cell wall synthesis inhibitors, protein synthesis inhibitors, DNA synthesis inhibitors, RNA synthesis inhibitors, mycolic acid inhibitors, and others. According to the report, cell wall synthesis represented the largest segment.

Cell wall synthesis is a class of antibiotics that target the bacterial cell wall. These antibiotics interfere with the process of cell wall synthesis, which causes cell wall damage and eventual bacterial death. In addition, penicillin, cephalosporins, and carbapenems are some of the cell wall synthesis inhibitors. They work by inhibiting enzymes called penicillin-binding proteins (PBPs) that are involved in the cross-linking of peptidoglycan chains. Moreover, cell wall synthesis inhibitors are particularly effective against gram-positive bacteria due to their thicker peptidoglycan layer, which provides a greater target for disruption.

Breakup by Drug Class:

  • Cephalosporin
  • Penicillin
  • Fluoroquinolone
  • Macrolide
  • Carbapenem
  • Aminoglycoside
  • Others


Penicillin accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes cephalosporin, penicillin, fluoroquinolone, macrolide, carbapenem, aminoglycoside, and others. According to the report, penicillin represented the largest segment.

Penicillin is a widely used class of antibiotics that belongs to the beta-lactam drug class. It works by inhibiting the synthesis of bacterial cell walls that causes cell wall damage and bacterial death. It is considered an essential medicine and is widely available as generic drugs. Apart from this, it is widely used in various healthcare settings, such as hospitals, clinics, and outpatient settings. In addition, the rising utilization of penicillin, as it is effective against various bacterial infections, is contributing to the growth of the market.

Breakup by Spectrum of Activity:

  • Broad-Spectrum Antibiotics
  • Narrow-Spectrum Antibiotics


Broad-spectrum antibiotics hold the biggest market share

The report has provided a detailed breakup and analysis of the market based on the spectrum of activity. This includes broad-spectrum antibiotics and narrow-spectrum antibiotics. According to the report, broad-spectrum antibiotics represented the largest segment.

Broad-spectrum antibiotics are a class of antibiotics that exhibit activity against a wide range of bacteria, such as gram-positive and gram-negative bacteria. In line with this, the rising adoption of broader spectrum antibiotics, as they are effective against a broader range of microorganisms compared to narrow-spectrum antibiotics, is bolstering the growth of the market. Apart from this, broad-spectrum antibiotics assist in treating infections when the causative bacteria are unknown or when the infection involves multiple bacterial species. The appropriate use of broad-spectrum antibiotics minimizes the risks of infections in the body.

Breakup by Route of Administration:

  • Oral
  • Parenteral
  • Topical
  • Others


Parenteral dominates the market segment

The report has provided a detailed breakup and analysis of the market based on the route of administration. This includes oral, parenteral, topical, and others. According to the report, parenteral represented the largest segment.

Parenteral antibiotics are administered via routes other than the digestive tract, such as intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes. These routes allow for direct delivery of the medication into the bloodstream or deep tissues, bypassing the gastrointestinal system. In addition, parenteral antibiotics provide rapid and predictable drug absorption and immediate therapeutic effect. They are also suitable for patients with compromised gastrointestinal function. Apart from this, it allows for accurate dosing and is particularly beneficial in cases where high drug concentrations are needed or when oral administration is not possible.

Breakup by End User:

  • Hospitals
  • Specialty Clinics
  • Others


Hospitals accounted for the largest market share

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, specialty clinics, and others. According to the report, hospitals represented the largest segment.

Antibiotics are widely consumed in hospitals due to the increased number of patients staying in this healthcare setting. Antibiotics are administered to patients admitted with severe infections. They are also administered before surgical procedures to reduce the risk of bacterial contamination. In line with this, the rising utilization of antibiotics among individual post-surgical prophylaxis is contributing to the growth of the market. Apart from this, the increasing consumption of antibiotics due to the rising risk of multidrug-resistant infections in hospitals is supporting the growth of the market.

Breakup by Region:

Antibiotics Market

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa


Asia Pacific exhibits a clear dominance, accounting for the largest antibiotics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific represented the largest market.

Asia Pacific held the biggest market share due to the improved healthcare infrastructure. In line with this, the growing prevalence of bacterial infections to poor sanitation is contributing to the growth of the market in the Asia Pacific region. Apart from this, the increasing demand for advanced antibiotics that can effectively combat multidrug-resistant bacteria is supporting the growth of the market. Furthermore, the presence of a large number of generic drug manufacturers is propelling the growth of the market in the region.

Competitive Landscape:

Key players in the industry are investing in research and development (R&D) activities to discover and develop new antibiotics and focusing on antibiotic resistance, expanding the spectrum of activity, and improving the efficacy and safety profiles of antibiotics. Apart from this, they are engaging in collaboration with research institutions, academic organizations, and government bodies to leverage their expertise and address the challenges associated with antibiotic development, such as high costs and regulatory compliances. Moreover, antibiotic companies are actively promoting antibiotic stewardship programs that encourage responsible and appropriate use of antibiotics to avoid overdosage and misusage. Furthermore, companies are increasingly conducting clinical trials and adhering to safety and efficacy standards to obtain regulatory approvals for their antibiotics.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Allergan Plc (AbbVie Inc.)
  • Basilea Pharmaceutica AG
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Melinta Therapeutics
  • Merck & Co. Inc.
  • Nabriva Therapeutics Plc
  • Paratek Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Spero Therapeutics
  • Tetraphase Pharmaceuticals


Recent Developments:

  • In 2021, Sandoz, a Novartis division, successfully completed the acquisition of GlaxoSmithKline’s (GSK) cephalosporin antibiotics business. This acquisition provides them rights to three established brands (Zinnat, Zinacef and Fortum) in more than 100 markets to Sandoz.

  • In January 2020, Merck & Co. Inc. announced that U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for DIFICID® (fidaxomicin) for oral suspension, and a supplemental New Drug Application (sNDA) for DIFICID tablets for the treatment of Clostridioides (formerly Clostridium) difficile-associated diarrhea (CDAD) in children aged six months and older.


Antibiotics Market Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Scope of the Report Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
  • Action Mechanism
  • Drug Class
  • Spectrum of Activity
  • Route of Administration
  • End User
  • Region
Action Mechanisms Covered Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, Mycolic Acid Inhibitors, Others
Drug Classes Covered Cephalosporin, Penicillin, Fluoroquinolone, Macrolide, Carbapenem, Aminoglycoside, Others
Spectrum of Activities Covered Broad-Spectrum Antibiotics, Narrow-spectrum Antibiotics
Routes of Administration Covered Oral, Parenteral, Topical, Others
End Users Covered Hospitals, Specialty Clinics, Others
Regions Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Allergan Plc (AbbVie Inc.), Basilea Pharmaceutica AG, GlaxoSmithKline Plc, Johnson & Johnson, Melinta Therapeutics, Merck & Co. Inc., Nabriva Therapeutics Plc, Paratek Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, Spero Therapeutics, Tetraphase Pharmaceuticals etc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Key Benefits for Stakeholders:

  • IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the antibiotics market from 2018-2032.
  • The research study provides the latest information on the market drivers, challenges, and opportunities in the global antibiotics market.
  • The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
  • Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the antibiotics industry and its attractiveness.
  • Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.

Key Questions Answered in This Report

The global antibiotics market was valued at US$ 51.4 Billion in 2023.

We expect the global antibiotics market to exhibit a CAGR of 3.5% during 2024-2032.

The rising prevalence of infectious diseases, such as pneumonia, urinary tract, skin, etc., along with the increasing utilization of antibiotics, as they assist in enhancing the immune system of individuals, is primarily driving the global antibiotics market.

The sudden outbreak of the COVID-19 pandemic had led to the growing number of R&D activities pertaining to specialty generic drugs for combating the spread of the coronavirus infection, thereby negatively impacting the global market for antibiotics drugs.

Based on the action mechanism, the global antibiotics market can be divided into cell wall synthesis inhibitors, protein synthesis inhibitors, DNA synthesis inhibitors, RNA synthesis inhibitors, mycolic acid inhibitors, and others. Currently, cell wall synthesis inhibitors account for the majority of the global market share.

Based on the drug class, the global antibiotics market has been categorized into cephalosporin, penicillin, fluoroquinolone, macrolide, carbapenem, aminoglycoside, and others. Among these, penicillin currently exhibits a clear dominance in the market.

Based on the spectrum of activity, the global antibiotics market can be segregated into broad-spectrum antibiotics and narrow-spectrum antibiotics. Currently, broad-spectrum antibiotics hold the largest market share.

Based on the route of administration, the global antibiotics market has been bifurcated into oral, parenteral, topical, and others, where parenteral currently accounts for the majority of the total market share.

Based on the end user, the global antibiotics market can be segmented into hospitals, specialty clinics, and others. Currently, hospitals exhibit a clear dominance in the market.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where Asia-Pacific currently dominates the global market.

Some of the major players in the global antibiotics market include Allergan Plc (AbbVie Inc.), Basilea Pharmaceutica AG, GlaxoSmithKline Plc, Johnson & Johnson, Melinta Therapeutics, Merck & Co. Inc., Nabriva Therapeutics Plc, Paratek Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, Spero Therapeutics, Tetraphase Pharmaceuticals, etc.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Antibiotics Market Report by Action Mechanism (Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, Mycolic Acid Inhibitors, and Others), Drug Class (Cephalosporin, Penicillin, Fluoroquinolone, Macrolide, Carbapenem, Aminoglycoside, and Others), Spectrum of Activity (Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics), Route of Administration (Oral, Parenteral, Topical, and Others), End User (Hospitals, Specialty Clinics, and Others), and Region 2024-2032
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More